Comparison of bleeding risk and hypofibrinogenemia-associated risk factors between tigecycline with cefoperazone/sulbactam therapy and other tigecycline-based combination therapies

• Główni autorzy: Lei Zhang (Autor), Xinfeng Cai (Autor), Fangchen Peng (Autor), Shuangshuang Tian (Autor), Xinjing Wu (Autor), Yun Li (Autor), Jinlin Guo (Autor)
• Format: Książka
• Wydane: Frontiers Media S.A., 2023-06-01T00:00:00Z.
• Hasła przedmiotowe: article
• Dostęp online: Connect to this object online.

Background: Tigecycline and cefoperazone/sulbactam can cause coagulation disorders; tigecycline may also lead to hypofibrinogenemia, raising safety concerns. This study aimed to investigate whether tigecycline plus cefoperazone/sulbactam increases the risk of bleeding compared with other tigecycline...